Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.

N.Iznaga Escobar,Patricia Lorenzo Luaces,Lizet Sanchez Valdes,Carmen Valenzuela Silva,Tania Crombet-Ramos,Dirk Strumberg,Beate Schultheis,Matthias P.A. Ebert,Andrea Kerkhoff,Ralf Hofheinz,Dirk Behringer,Wolfgang E. Schmidt,Erdem Goker,Sara De Dosso,Michael Kneba,Şuayib Yalçin,Friedrich Overkamp,Frank Schlegel,Markus Dommach,Robert Rohrberg

Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.

2017

e15787Background: Nimotuzumab, a unique and affinity differentiated anti-EGFR antibody had been used in combination with gemcitabineon the treatment of pancreatic cancerpatients. The aim of the s...

Keywords:

Metastatic pancreatic cancer
Oncology
Pathology
Medicine
Internal medicine
Nimotuzumab
Pancreatic cancer
Antibody
overall survival
Gemcitabine
locally advanced
third line

Correction
Source
Cite
Save

References

Citations